Journal
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
Volume 14, Issue 6, Pages 485-489Publisher
SPRINGER JAPAN KK
DOI: 10.1007/s10147-009-0942-z
Keywords
Melanoma; Sentinel lymph node biopsy; Lymph node dissection; Staging tool; Prognostic value; Therapeutic effect
Categories
Funding
- Ministry of Health, Labour and Welfare, Japan [H19-clinical trial-general-018]
Ask authors/readers for more resources
The notion of sentinel lymph node (SLN) mapping and its use during surgery for staging cancer was initially reported in 1992, in a study involving patients with malignant melanoma. To date SLN biopsy (SLNB) has emerged as a rational approach for staging regional lymph nodes in patients with clinically node-negative melanoma (stage I and II disease). The significance of SLNB as a staging and prognostic tool in melanoma is widely accepted. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of the SLN remains very controversial. Whether SLNB improves survival in melanoma patients remains an open question.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available